Dr. Landau brings over 28 years of pharmaceutical experience in both the branded and generic sectors with a wealth of highly successful R&D, manufacturing and commercial experiences. His proven record of taking customer-centric pharmaceutical companies to the next level will significantly augment Frontida’s management team and guide the next steps of the company’s growth.
Previously, Dr. Landau led key functions at mid-to large scale pharma companies including Merck, Novartis, Fougera, and Sandoz. Dr. Landau also has significant experience with compliance initiatives, having remedied some considerable regulatory challenges during his career.
Frontida BioPharm chairman, Dr. Song Li, said, “Dr. Landau’s vision is to grow the company by focusing on both our CDMO heritage and importantly, the potential our capabilities afford. In particular, Dr. Landau will place emphasis on leveraging our R&D skills and manufacturing capacities to develop strong business partnerships where we can share the true potential of commercializing FDA-approved therapies. The combination of his experience, knowledge, drive and culture-building skills make Dr. Landau an ideal fit for Frontida‘s next stages of growth.”